Targeting MET Amplification: Vebreltinib Shows Robust Antitumor Activity in Advanced NSCLC
The Phase 2 KUNPENG trial demonstrates that vebreltinib, a selective MET inhibitor, achieves a 48.8% objective response rate in patients with MET-amplified advanced non-small-cell lung cancer, regardless of prior treatment history, offering a promising targeted therapy for this difficult-to-treat molecular subgroup.